Kim Kardashian Was Diagnosed With Psoriatic Arthritis After Her Lupus Scare On ‘KUWTK’ – Women’s Health

Posted on September 22, 2019 by Dook Domini

Axelle/Bauer-GriffinGetty Images

Kim Kardashian's health woes have been a major plot line for the new season of Keeping Up With The Kardashians. On last week's episode, Kim underwent testing for lupus and rheumatoid arthritis antibodies after she said she'd been experiencing numbness in her hands and other symptoms, and tested positive.

Ive been feeling so tired, so nauseous and my hands are really getting swollen, she said. I feel like I literally am falling apart. My hands are numb. Lately, my wrists are starting to hurt again but its definitely a different feeling, she said. I feel this in my bones. Its starting to really worry me. I really have to look into this. Based on the symptoms, it looks like I have rheumatoid arthritis. Its so scary. So I have to go to the doctor and see whats going on because I cant live like this.

But she still didn't have exact answers for what was going on. On last night's episode of KUWTK, Kim finally learned what was causing her pain.

In the episode, she went to a doctor and had an ultrasound done on her hands to determine whether or not she was suffering from lupus or rheumatoid arthritis. And it turns out, she was diagnosed with psoriatic arthritis.

First of all, if you have any evidence for lupus, we would have screened it, the doctor explained. You do not have lupus and rheumatoid arthritis. So, you can be reassured. You probably have psoriatic arthritis because psoriasis comes and goes. Theres nothing there right now.

Kim immediately let out a deep breath after hearing the news. Im so relieved that this is just psoriatic arthritis, Kim admitted. The pain is going to come and go sometimes, but I can manage it and this isnt going to stop me.

According to the American College of Rheumatology, psoriatic arthritis is a form of inflammatory arthritis that happens to people with psoriasis. Kim's been open about her struggles with the skin condition psoriasis in the past.

The main symptoms of psoriatic arthritis are painful, stiff and swollen joints. While the cause of psoriatic arthritis is not known, of those with psoriatic arthritis, 40 percent also have a family member with psoriasis or arthritis, according to the American College of Rheumatology.

It's not unusual for someone Kim's age to be diagnosed with psoriatic arthritispeople between 30 and 50 years old are the most likely to be diagnosed, per the American College of Rheumatology. And while there is no cure for psoriatic psoriasis, treatments usually involve over-the-counter anti-inflammatories or prescription anti-rheumatic drugs.

Here's hoping Kim finds a resolution to her symptoms soon.

Follow this link:

Kim Kardashian Was Diagnosed With Psoriatic Arthritis After Her Lupus Scare On 'KUWTK' - Women's Health

Psoriasis Drug Target Holds Potential for Bone Cancer – Technology Networks

Posted on September 22, 2019 by Dook Domini

Using a mouse model, researchers have discovered a potential therapeutic target for osteosarcoma one which is already used to treat psoriasis. These new findings are published in Cancer Discovery.

Not just "growing pains"

Osteosarcoma is a type of bone cancer, commonly diagnosed in young people; around half of new cases in the United States each year are in children and teenagers. As such, the signs and symptoms can often be mistaken for "growing pains", which can delay diagnosis. If, by this point, the cancer has spread outside the bone, five-year survival rates decrease from 77% to 65%.

Current treatment for osteosarcoma follows a standard pattern; surgery, chemotherapy and/or radiotherapy. Given the survival rate, there are efforts to develop treatments beyond this standard. One such treatment is immunotherapy, which is rapidly becoming the fifth pillar of cancer treatment.1

The role of the immune system

Researchers were led towards immune molecules by the results of genome-wide association studies (GWAS), which associated the gene GRM4 with susceptibility to osteosarcoma.2,3 It was through investigating this gene that they found an association between osteosarcoma and IL-23, a pro-inflammatory molecule within the immune system.

In a recent press release, lead author Maya Kansara says : "In a mouse model of osteosarcoma, we investigated the role of GRM4, as well as a number of immune molecules, the production of which is regulated by GRM4," she continues: "In our model, we discovered that the inflammatory molecule IL-23 was critical to osteosarcoma formation and progression."

The authors uncovered the role of IL-23 by removing it from mice, via a gene knock-out, finding that they were then protected from developing osteosarcomas. Blocking IL-23 in mice with existing osteosarcomas was also trialed the growth of these tumors was successfully suppressed.4From bench to bedside

The relationship between IL-23 and development of osteosarcoma suggests the former could be targeted in treatment of the latter. IL-23 is already a target in the treatment of some autoimmune diseases, including psoriasis.

"Drugs that block IL-23 are approved and well-tolerated, and on the market now for the treatment of psoriasis," says Professor David Thomas, co-author of the study. "We are now designing clinical trials to see whether they can provide much-needed improved health outcomes for osteosarcoma patients."

References

1.Oiseth, S.J., Aziz, M.S. (2017) Cancer immunotherapy: a brief review of the history, possibilities, and challenges ahead. Journal of Cancer Metastasis and Treatment. DOI: https://doi.org/10.20517/2394-4722.2017.41

2.Savage, S.A., et al. (2013) Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nature Genetics. DOI: https://dx.doi.org/10.1038%2Fng.2645

3.Jiang, C., et al. (2014) GRM4 gene polymorphism is associated with susceptibility and prognosis of osteosarcoma in a Chinese Han population. Medical Oncology. DOI: https://doi.org/10.1007/s12032-014-0050-4

4.Kansara, M., et al. (2019) Infiltrating myeloid cells drive osteosarcoma progression via GRM4 regulation of IL23. Cancer Discovery. DOI: https://doi.org/10.1158/2159-8290.CD-19-0154

High blood pressure risk in psoriasis, psoriatic arthritis – Dermatology Times

Posted on September 22, 2019 by Dook Domini

Psoriasis and psoriatic arthritis are relatively common immune mediated diseases. The increase in cardiovascular disease associated with psoriatic disease is well established. Interestingly, some studies suggest a stronger link between psoriatic arthritis and cardiovascular disease.

Hypertension is a major risk factor for the development of cardiovascular disease. It is therefore considered an important modifiable risk factor in the development of cardiovascular disease. Previous studies have shown that patients with psoriasis have an increased risk of poorly controlled hypertension. Furthermore, there appears to be an increased prevalence of hypertension in patients with psoriatic arthritis even after adjusting for traditional cardiovascular risk factors.

RELATED:Cardiovascular risk associated with psoriasis patients age, race

A group of collaborating physicians from Hospital Universitario Central de Asturias (HUCA), Spain, led by Dr. Ruben Queiro performed an observational cross-sectional study to analyze the comparative prevalence of hypertension in psoriatic disease.

The patient cohort was from a multidisciplinary (rheumatology/dermatology), single center clinic, in a university hospital in Spain. 290 patients with psoriatic arthritis and 310 patients with psoriasis (in the absence of psoriatic arthritis) were included. For the purpose of the study hypertension was defined as 140/90 on two separate days during a one month period or the chronic use of antihypertensive medication.

The study cohort was composed of 324 men and 276 women with a mean age of 5312 years. The study results showed the following: 144/600 patients had hypertension (24%). The mean age at onset of psoriasis and arthritis was significantly higher in the hypertension population (3917 in HBP vs. 2616 years in non-HBP, p<0.01, 4917 in HBP vs. 4114 years in non-HBP, p<0.01). The mean body weight and BMI were significantly higher in HBP patients (8316 in HBP vs. 7715 kg in non-HBP, p<0.01, 30.24.9 in HBP vs. 274.4 in non-HBP, p<0.01).

References:

Queiro R, Lorenzo A, Tejn P, Pardo E, Coto P. Hypertension is associated with increased age at the onset of psoriasis and a higher body mass index in psoriatic disease. Clin Rheumatol. 2019;38(8):2063-2068.

Continued here:

High blood pressure risk in psoriasis, psoriatic arthritis - Dermatology Times

Psoriasis cant be cured, but new treatments can clear skin in many – Pocono Record

Posted on September 22, 2019 by Dook Domini

Plaque psoriasis is a common skin condition that causes raised red patches covered with a silvery white buildup of dead skin cells to form. Plaque psoriasis is the most common form of psoriasis about 80 to 90% of the 7 million to 8 million Americans who have psoriasis have plaque psoriasis, according to the National Psoriasis Foundation.

Plaque psoriasis is most commonly found on the scalp, elbows, knees and lower back, but it can affect anywhere on the body, says Dr. Alan Westheim, dermatologist at St. Lukes Medical Associates of Monroe County in East Stroudsburg. The plaques can be itchy and painful, he says.

Because psoriasis can be unsightly, many fear it is contagious, but it is not, Westheim says. It cant be spread by touch or by close contact, he says. We also know that psoriasis has a large effect on the patients quality of life.

Psoriasis is an autoimmune disease, Westheim explains. That means the body sees its own cells as foreign invaders and attacks them. The attacks cause the skin to grow more quickly, Westheim says. Normal skin replenishes every five to six weeks, Westheim says. When you have psoriasis, your skin replenishes every five to six days.

It isnt known why some people get psoriasis and others dont, Westheim says. Genetics is believed to play a role. About 10% of people are born with genes that make them prone to psoriasis, but only about 3% of people get psoriasis. Obesity also appears to play a role; the greater your weight, the greater likelihood of developing psoriasis, he says.

If both parents have psoriasis, their children are more likely to get psoriasis, too, Westheim says.

You can get psoriasis at any age, even as an infant, Westheim says. However, it is most common when people are in their late teens and early 20s and again after age 60.

Topical, systemic treatments available

There is no cure for psoriasis, but it can be treated, Westheim says. Some people are able to achieve clear skin with the newer treatments available. The newer treatments are designed to stop the immune process that leads to plaques.

When it comes to treatment, theres a ladder we climb, Westheim says. We try one treatment, and if that doesnt work, we go onto the next.

Depending on the severity of your psoriasis, your doctor may recommend topical treatments topical creams and steroids and vitamin D derivatives, he says. If you respond, great. If you dont, we might try UV light treatments. And if that doesnt work, we can talk about medications.

Methotrexate had been the mainstay for many years, but now there are a number of newer drugs on the market, Westheim says. The newer medicines are biologics and work wonderfully but are costly around $20,000 a year, he says.

Treatments are important to prevent disease progression and joint destruction, he says. It is important to look at psoriasis as a systemic disease as there is associated risk for heart disease and other systemic illnesses.

About a third of people with psoriasis also develop psoriatic arthritis, which can cause joint pain and swelling, Westheim says.

View post:

Psoriasis cant be cured, but new treatments can clear skin in many - Pocono Record

Anti-psoriasis compound could lead to new drug for malaria – Futurity: Research News

Posted on September 22, 2019 by Dook Domini

Share this Article

You are free to share this article under the Attribution 4.0 International license.

Redesigning molecules originally developed to treat the skin disease psoriasis could lead to an effective new drug against malaria, according to new research.

Researchers modified a class of molecules called pantothenamides to increase their stability in humans. The new compounds stop the malaria parasite from replicating in infected humans and from being transmitted to mosquitoes. Theyre also effective against malaria parasites resistant to currently available drugs.

Malaria is a major global health concern, with around 216 million cases and 400,000 deaths annually. The deadliest form of the disease is caused by the parasite Plasmodium falciparum, which is transmitted to humans from the bite of an infected Anopheles mosquito. Because many Plasmodium parasites have developed resistance to the most common drugs used against them, there is a pressing need for effective new treatment options.

We have known for a long time that pantothenamides are extremely potent against the malaria parasite, but they become unstable within biological fluids because an enzyme clips them apart before they can act, says coauthor Manuel Llins, professor of biochemistry and molecular biology and of chemistry at Penn State. The researchers found that changing a chemical bond in a pantothenamide molecule prevents this clipping, making it viable for use as a new antimalarial drug, he says.

The team found that the modified pantothenamide molecules not only interfere with the development of the malaria parasite during its asexual growth phase in the blood but also prevent transmission of the sexual form of the parasite from human blood to mosquitoes.

By also preventing the transmission of malaria parasites from infected people into mosquitoes, these pantothenamides can reduce the chances that mosquitoes will be infectious to others, says Llins. It is currently widely accepted that next-generation antimalarial drugs must target the parasite at multiple stages to both cure the disease in an infected individual and prevent its spread to others.

Llins and Erik Allman, postdoctoral scholar at Penn State at the time of the research, investigated exactly how the four most potent molecules in the compound class kill the malaria parasite. Specifically, they examined how these compounds affect the parasites metabolism while growing in human blood.

The team discovered that, because the pantothenamide molecule closely resembles the essential vitamin B5, the parasite mistakenly takes it in and metabolizes it. This leads to the formation of molecular analogues, or antimetabolites, which decrease the parasites production of acetyl-CoA, a compound critical for its survival.

The molecule has a mechanism of action that hasnt been used before, says Koen Dechering, of TropIQ Health Sciences. This means that theres no resistance to the drug as yet, and it is effective against many forms of malaria. Because parasite resistance to malaria drugs is a major problem worldwide, we are very close to a breakthrough.

Pantothenamides have a simple chemistry, so they are easy and inexpensive to make, says Llins, And we now know their mode of action, which we dont always know before moving into drug development. This makes pantothenamides excellent candidates for further development and eventual clinical trials.

The research appears in the journal Science Translational Medicine.

Additional researchers from Penn State, Radboud University Medical Center in the Netherlands, St. Judes Childrens Research Hospital, Chiralix in the Netherlands, XenoGesis in the United Kingdom, the Swiss Tropical and Public Health Institute in Switzerland, the University of Basil in Switzerland, the Art of Discovery in Spain, Medicines for Malaria Venture in Switzerland, and Hermkens Pharma Consultancy in the Netherlands contributed to the work.

Source: Penn State

Go here to see the original:

Anti-psoriasis compound could lead to new drug for malaria - Futurity: Research News

Guselkumab Demonstrates Superiority to Secukinumab for Reducing Psoriasis Area and Severity – Dermatology Advisor

Posted on September 22, 2019 by Dook Domini

Guselkumab administered at 100 mg for 5 weeks and then every 8 weeks was superior to secukinumab at 300 mg for 5 weeks and then every 4 weeks in inducing a 90% reduction in the Psoriasis Area and Severity Index (PASI 90) response at 48-week follow-up, a phase 3 study in the Lancet suggests.

Patients aged 18 years who had moderate to severe plaque-type psoriasis were enrolled in the trial. The study was a comparator-controlled analysis conducted at 142 outpatient centers in nine countries. Only patients who were candidates for phototherapy or systemic therapy were eligible to participate. Study investigators randomly assigned patients to either 100 mg guselkumab at week 0 and week 4 and then every 8 weeks (n=534) or 300 mg secukinumab at weeks 0, 1, 2, 3, and 4, and then every 4 weeks (n=514).

The proportion of patients who achieved a 90% reduction in PASI 90 response at week 48 comprised the primary endpoint. Additional secondary endpoints included the proportion of patients who achieved a PASI 75 response at weeks 12 and 48, PASI 90 response at week 12, PASI 75 response at week 12, PASI 100 response at week 48, Investigators Global Assessment score of 0 (cleared) at 48 weeks, and Investigators Global Assessment score of 0 or 1 (minimal) at 48 weeks. In patients who received 1 dose of their assigned study drug from week 0 to week 56, safety was also assessed.

At 48 weeks, a higher proportion of patients who achieved a PASI 90 response was observed in the guselkumab group vs the secukinumab group (84% vs 70%, respectively; P <.0001). Guselkumab was noninferior to secukinumab in terms of the proportion of patients who achieved a PASI 75 response at both week 12 and week 48 (85% vs 80%, respectively; treatment difference, 4.3 percentage points; 95% CI, 0.2 to 8.9; P <.0001). The researchers were unable to establish superiority of guselkumab for PASI 75 at these time points (P =.0616). There was no difference between the groups with regard to the rate of adverse events, infections, or serious adverse events.

Limitations of the study were the lack of assessment of drug concentrations as well as the data projecting longer than 1 year.

The researchers added that blocking the regulatory capacity of the [interleukin]-23 pathway with guselkumab rather than directly targeting interleukin-17A with secukinumab might be useful for maintaining a durable response and preventing recurrence of disease in patients with psoriasis.

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

Follow @DermAdvisor

Reference

Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831-839.

Read the original:

Guselkumab Demonstrates Superiority to Secukinumab for Reducing Psoriasis Area and Severity - Dermatology Advisor

Patients With Psoriasis Have 2-Fold Higher Risk of Mortality – Dermatology Advisor

Posted on September 22, 2019 by Dook Domini

In the United States, patients with psoriasis have a 2-fold higher risk for mortality compared with individuals without psoriasis, a study in the Journal of the American Academy of Dermatology suggests. The risk for mortality in these patients appears to be partially mediated by the higher prevalence of infectious, cardiovascular, and neoplastic disorders that are frequently observed in patients with psoriasis.

The ongoing, cross-sectional National Health and Nutrition Examination Survey (NHANES) was used to identify patients aged >10 years with self-reported psoriasis (n=347) and control patients without psoriasis (n=12,684). Only individuals who participated in the NHANES between 2003 and 2006, as well as 2009 and 2010, were included in the retrospective study.

Medical history questionnaires were used to assess participants comorbidities, including history of cancer, cardiovascular disease, chronic kidney disease, and diabetes mellitus. Data linked from national databases were examined to identify associated mortality rates.

The presence of psoriasis was associated with a 1.99-fold higher risk for mortality during a 52.3-month follow-up period compared with nonpsoriatic control patients (hazard ratio, 1.99; 95% CI, 1.01-3.93; P =.047), according to the adjusted analysis. Female sex and income were associated with a lower mortality risk, whereas smoking and increasing age drove the higher risk for mortality. Comorbidities that partially mediated the increased risk for mortality in patients with psoriasis included cardiovascular disease (15.5%), chronic obstructive pulmonary disease (8.7%), cancer (11.7%), diabetes mellitus (5.9%), chronic kidney disease (4.2%), and stroke (4.7%).

Limitations of the analysis include its retrospective nature, as well as the self-reported nature of some of the data.

Considering the different guidelines and use of systemic therapies between countries, the researchers wrote, future population-based studies investigating the effect of systemic therapies on mortality risk are essential for understanding the long-term effects of these medications.

Follow @DermAdvisor

Reference

Semenov YR, Herbosa CM, Rogers AT, et al. Psoriasis and mortality in the US: Data from the National Health and Nutrition Examination Survey [published online August 12, 2019]. J Am Acad Dermatol. doi:10.1016/j.jaad.2019.08.011

More here:

Patients With Psoriasis Have 2-Fold Higher Risk of Mortality - Dermatology Advisor

J&J Files sBLA for Tremfya With FDA for Psoriatic Arthritis – Yahoo Finance

Posted on September 22, 2019 by Dook Domini

Johnson & Johnson JNJ submitted a supplemental biologics license application (sBLA)to the FDA, seeking approval to expand the label of itsIL-23 inhibitor Tremfya as a treatment for active psoriatic arthritis (PsA).

The sBLA filing was based on data from the phase III DISCOVER 1 and 2 studies, which evaluated the safety and efficacy of Tremfya compared to placebo for treating adult patients with PsA.

In June, J&Js subsidiary, Janssenhad announced top-line results from the studies, which evaluated Tremfya administered by subcutaneous injection. The studies met the primary endpoint of achieving American College of Rheumatology 20% improvement while the safety profile was consistent with the previous programs on Tremfya/guselkumab.

J&J expects to file a similar regulatory application with the European Medicines Agency by the end of this year.

J&Js stock has risen 0.4% this year so far against a decrease of 1.9% recorded by the industry.

Tremfya was first approved in the United States and the EU in 2017 for the treatment of moderate-to-severe plaque psoriasis and was off to a solid start after its launch.

The drug recorded sales of $452 million in the first half of 2019. If approved by the FDA for PsA, Tremfya will be the first IL-23 inhibitorto be approved to treat this complex inflammatory disease, which causes pain, stiffness and swelling in and around the joints. It will expand the drugs eligible patient population and should boost its sales.

Tremfya has proved its superiority over other drugs in the past. Last December, J&J announced results from a head-to-head phase III ECLIPSE study, which compared Tremfya with Novartis' NVS psoriasis drug, Cosentyx (secukinumab).

Data from the study showed that after a 48-week treatment, 84.5% of the patients treated with Tremfya achieved 90% improvement in disease symptoms as measured by the Psoriasis Area Severity Index in comparison to 70% achieved by Novartis' Cosentyx.

The drug is also being studied for various other indications including phase IIb/III studies in Crohns disease and ulcerative colitis and in a phase II study for hidradenitis suppurativa.

J&J currently has a Zacks Rank #3 (Hold). Some better-ranked large-cap pharma stocks include Roche Holding AG RHHBY and Merck MRK, both with a Zacks Rank #2 (Buy). You can see the complete list of todays Zacks #1 Rank (Strong Buy) stocks here.

Shares of Roche have gained 10.8% this year so far. Earnings estimates for 2019 have risen 0.8% while that for 2020 have increased 2% over the past 60 days.

Mercks stock is up 7.3% this year so far. Its earnings estimates have risen 3.6% for 2019 and 1.3% for 2020 over the past 60 days.

5 Stocks Set to Double

Zacks experts released their picks to gain +100% or more in 2020. One is a famous cutting-edge food company that is hiding in plain sight. Swamped with competitors and ignored by Wall Street, its stock price floundered. Now, suddenly, it acquired a company that gives it an advantage none of its peers have.

Today, see all 5 stocks with extreme growth potential >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportRoche Holding AG (RHHBY) : Free Stock Analysis ReportJohnson & Johnson (JNJ) : Free Stock Analysis ReportMerck & Co., Inc. (MRK) : Free Stock Analysis ReportNovartis AG (NVS) : Free Stock Analysis ReportTo read this article on Zacks.com click here.

J&J Files sBLA for Tremfya With FDA for Psoriatic Arthritis - Yahoo Finance

J&J’s Tremfya filed for approval in US for psoriatic arthritis – PMLiVE

Posted on September 22, 2019 by Dook Domini

Johnson & Johnson has submitted an application to the FDA for the approval of Tremfya in psoriatic arthritis, which could further congest an intensely competitive therapy area.

Tremfya (guselkumab) is Janssens follow-up to IL-23/IL-12 inhibitor blockbuster Stelara (ustekinumab), which has faced competition from rival new treatments across immunology indications.

This includes Novartis Consentyx (secukinumab), AbbVies Skyrizi (risankizumab), Eli Lillys Taltz (ixekizumab) and Pfizers Xeljanz (tofacitinib citrate) , which are all already approved in psoriatic arthritis.

The application to the FDA is based on thetop line results from the pivotal phase 3 trials of Tremfya, DISCOVER-1 and DISCOVER-2.

The drug hit its primary endpoint of ACR20 response at week 24, and multiple secondary endpoints including ACR50/70, resolution of soft tissue inflammation (enthesitis and dactylitis), disease activity (DAS-28 CRP), improvement in physical function (HAQ-DI), skin clearance (IGA) and quality of life (SF-36 PCS and MCS).

DISCOVER-2 also assessed the effect on structural damage using the van der Heide-Sharp score as a key endpoint. DISCOVER-1 studied Tremfya in 381 participants, including some who were previously treated with anti-TNF biologics, and the duration of the study was 52 weeks. DISCOVER-2 included 739 biologic-naive participants, and continued up to 100 weeks.

J&J will face tough competition from other psoriasis therapies, including Novartis Cosentyx. The two drugs both treat psoriasis by targeting interleukins involved in the inflammatory process, with Consentyx targeting IL-17 and Tremfya inhibiting IL-23, and they are among a crowd of new biologic therapies vying for market share in the psoriasis category.

Despite the competition, Tremfya is still a source of growth for J&J sales of Tremfya, which came to market in 2017, totalled $452m over the first half of 2019. With a successfulhead-to-head trial against Novartis Cosentyx in plaque psoriasis under its belt, J&Js drug has been established as a significant contender in the crowded field of psoriasis drugs.

However, J&J has been subject to another head-to-head trial Eli Lillys Taltzoutperformed Tremfya in a post-marketing trial in patients plaque psoriasis.

Taltz already has a large portion of the market share, having generated sales of $606m over the first half of 2019, which suggests full-year revenues will beat the $938m it brought in last year.

Lillys Taltz has also been proved to be superior to market leader Humira (adalimumab), in reducing psoriatic arthritis activity by half, and also completely cleared patients skin after 24 weeks. These factors could damage Tremfyas uptake in this indication, if approved, but its already established presence in the field could counteract this.

AbbVies Humira and J&Js Stelara have remained blockbuster drugs, partly due to their ability to rapidly clear up 75% of lesions in most patients.

J&J is also set to submit a marketing application to the European Medicines Agency for Tremfya in the same indication before the end of the year.

Originally posted here:

J&J's Tremfya filed for approval in US for psoriatic arthritis - PMLiVE

Cayenne Pepper Relieves Joint Pain, Treats Psoriasis And Other Health Benefits – Medical Daily

Posted on September 22, 2019 by Dook Domini

Cayenne pepper is more than just another spice since it has been providingmany medicinal benefits for thousands of years. The healing properties come from an active component of the chili pepper called capsaicin, which provides the hot taste. The level of spice corresponds to the amount of capsaicin it contains, therefore beinghealthierif morecapsaicinis present.

However, cayenne pepper is moderately hot in general. Introduced to European continent by Christopher Columbus in the 15th century, it was grown originally in Central and South America. Nowadays, you can grow cayenne pepper seedlings in your balcony or garden.

Cayenne peppers can be eaten in natural, powdered, cream and capsule form. It has a rich nutritional profile with one tablespoon or 5 grams of pepper containing 17 calories, 44 percent of the required daily intake (RDI) of vitamin A, 8 percent of vitamin E, 7 percent of vitamin C and 6 percent of the vitamin B6. Here are some of the major health benefits of incorporating cayenne peppers into your meals.

Anti-Cancer Properties

Capsaicin is the ingredient that helps reduce the risk of cancers such as lung, pancreatic, prostate and skin cancer. It attacks the cancer cells' growth process from all of its pathways. A study conducted by the University of California proved this. So far, the findings are limited to animal and laboratory studies. More studies based on human beings are required for further verification.

Brings Down Psoriasis

Psoriasis is an autoimmune disease that causesinflammation on the skin due to excessive skin production. It manifests in the form of scaly skin with white itchy patches. According to Dr.Axe.com, two trials involving the topical application of capsaicin cream of just 0.025 percent was successful in healing somepsoriasis wounds. During a six weeks period, 44 patients had shown a decrease of psoriasis symptoms such as scaling and redness.

The next study consisted of 197 patients who were similarly treated topically with capsaicin cream four times every day for six week showed a similar reduction in skin destruction.Capsaicin also helped in bringing down the amount of substance P, a small peptide, that is involved in the formation of psoriasis.

Relieves Joint and Nerve Pain

Substance P is released in abnormal amounts in people with fibromyalgia. It is a neurotransmitter that signals pain to the brain. When there are fewersignals, small amounts of substance P is produced, whichmeans there is lesspain experienced.Cayenne pepper has the power to alleviate pain when applied on the skin to treat osteoarthritis, rheumatoid arthritis, nerve damage and lower back injuries.

Supports Weight Loss and Aids Digestion

Cayenne pepper reduces appetite and helps promote weight loss if consumed for breakfast. It also burns fat by increasing the heat generated by the body internally, which eventually leads to an increase in the metabolic rate.

Cayenne pepper increases the production of saliva in the salivary glands, which is the first crucial step in the digestive process. It also helps generate gastric juices that aid the digestive process too. The peppers help flush out toxins out of the body and produce a detoxifying effect.

Helps Overcome Cold and Flu

Cayenne pepperis a source of vitamin C, which could help reduce the cold accompanying a flu. It is also a natural remedy for the flu because it helps in decongesting the mucus and helps it exit the body.Also, its antioxidants could boost your immune system.

Hot Cayenne chili peppers are displayed at the Royal Horticultural Society (RHS) Harvest Festival Show on October 9, 2013 in London, England. The nation's enthusiasts are showcasing their finest home grown fruit and vegetables for two days at the RHS Horticultural Hall. Photo by Peter Macdiarmid/Getty Images

Here is the original post:

Cayenne Pepper Relieves Joint Pain, Treats Psoriasis And Other Health Benefits - Medical Daily

Kim Kardashian diagnosed of psoriatic arthritis. Here is what it is – Times of India

Posted on September 22, 2019 by Dook Domini

Despite all the fame and money which comes your way, bad health has a way of striking on your doors when you are least expecting it. Kim Kardashian knows this very well.Hollywood celebrity, reality TV star, and entrepreneur, Kim Kardashian recently opened up about receiving a "scary" health diagnosis from her doctor which made her question her life choices and worry what the future held for her.In one of the episodes of her show, Kim can be seen paying a visit to the doctor's clinic, where she received a rather scary diagnosis about contracting lupus, which later turned out to be false. As the mother of four said, she had been feeling a certain numbness in her hands and felt really tired of late, making her worry:

The 38-year-old star also talked about how the diagnosis made her question her life choices. She also said that the lupus diagnosis made her undergo depression.

'When you do have a diagnosis, or you get tested for something and you get a result that you weren't expecting, you definitely get in your head and for a second you kinda get this little depression of, like, "OK, what are all of the possibilities that can happen?"' the star said.

'"What's my life gonna look like? I really wanna be active for my kids." And so it triggers something,'

However, she took it in her stride and decided to look at the positive side of life for the sake of her four kids and family. In an interview, she added:

No matter what's going on in your life, you can take that time to grieve for a second and then figure out how to be positive about it because it's not going to change. 'There's no point in being depressed and staying in that headspace, but I felt it for a minute", she added.

Kim, who has been a patient of psoriasis for a long time now had to go through screenings and tests, which revealed that she tested positive for certain antibodies responsible for the spread of lupus and rheumatoid arthritis.

However, the diagnosis proved to be false and Kim breathed a sigh of relief. While she did test positive for some antibodies, it was later revealed that she was suffering from psoriatic arthritis, a less severe form of arthritis.

Follow this link:

Kim Kardashian diagnosed of psoriatic arthritis. Here is what it is - Times of India

Psoriatic Arthritis: Facts About Kim Kardashian-Wests Disease Following Diagnosis – Medical Daily

Posted on September 22, 2019 by Dook Domini

Last week's episode of "Keeping Up With The Kardashians" (KUWTK) sparked concerns about Kim Kardashian-West. She got tested for lupus and rheumatoid arthritis then was diagnosed with a different condition.

Kim has psoriatic arthritis. It is a form of inflammatory arthritis affecting people with psoriasis and causes red patches of skin topped with silvery scales.

Prior to her diagnosis, the mother of four and wife of rapper Kanye West has been vocal about her psoriasis in previous episodes of KUWTK.

Psoriatic arthritis affects any part of the body, from fingertips to the spine. It may cause joint pain, stiffness and swelling.

Kim decided to meet a doctor to check her condition after experiencing numbness in her hands. She also reported feeling tired and nauseous and having swollen hands.

I feel like I literally am falling apart. My hands are numb. Lately, my wrists are starting to hurt again but its definitely a different feeling, she said as quoted by Womens Health. I feel this in my bones. Its starting to really worry me. I really have to look into this.

Kim initially suspected that she had rheumatoid arthritis and lupus. But the doctor who checked her did not find signs of the disease.

However, she appeared with symptoms of psoriatic arthritis. The doctor said the condition commonly comes and goes, which explains the pain and changes on Kims body.

Psoriatic arthritis commonly affects people at ages between 30 and 50, according to the American College of Rheumatology. But this condition can be tricky and sometimes hard to detect because of common symptoms that also appear in other conditions.

Psoriatic Arthritis Facts You Need to Know

No Cure

Psoriatic arthritis can be disabling if left untreated. However there is no cure available for this condition, according to the Mayo Clinic.

Doctors commonly recommend over-the-counter anti-inflammatories or prescription anti-rheumatic drugs to control its symptoms and protect the joints.

Psoriatic Arthritis Can Cause Sausage-Like Swelling

Some people who develop psoriatic arthritis may experience painful, sausage-like swelling of fingers and toes. It may also lead to deformities in both hands and feet. The pain can travel to tendons, ligaments and lower back.

Psoriatic Arthritis Cause Still a Mystery

Health experts said they have yet to fully understand how psoriatic arthritis occurs. Studies suggested it begins when the immune system attacks healthy cells and tissue, which triggers inflammation in the joints and overproduction of skin cells.

However, the question remains of why the immune system starts the abnormal response.

Family History Plays a Role

Scientists said there can be genetic factors contributing to psoriatic arthritis. A number of studies showed that many people with close relatives who developed the condition also appeared with psoriatic arthritis later in life.

Meanwhile, Kim did not look at her condition as very serious problem. She said she was relieved that this is just psoriatic arthritis.

The pain is going to come and go sometimes, she said. But I can manage it and this isnt going to stop me.

TV personality Kim Kardashian attends the 2018 MTV Movie And TV Awards at Barker Hangar on June 16, 2018 in Santa Monica, California. There are simple ways to spot the early signs of psoriasis when one has a chronic or seasonal dry skin, which may appear similar to the disease. Emma McIntyre/Getty Images

Kim Kardashian gets brutally honest about her psoriasis as she shares defiant photos of sores – Herald Publicist

Posted on September 22, 2019 by Dook Domini

After being recognized with psoriatic arthritis, fearing it was lupus, Kim Kardashian has opened up about her battle with psoriasis, sharing a defiant selfie throughout a flare up.

The 38-year-old star has battled the autoimmune situation for a while, nevertheless right this moment she shared an in depth and private essay about her journey with the sickness.

Writing on her sister Kourtneys way of life web site Poosh, Kim revealed she first began to get psoriasis signs on her twenties, when a standard chilly triggered the situation and he or she had it all over her stomach and legs, earlier than it got here again with a vengeance in her thirties.

Earlier this year is when it got extremely badit covered my whole face and a majority of my entire body, the 38-year-old informed readers.

Sharing a group of photographs of her flare ups, she needed to indicate everybody what she goes by way of, with painful trying marks and purple scabs dominating her legs.

It was shedding the motion in her arms as a result of situation that had Kim getting the assessments we noticed in a current episode of Preserving Up With The Kardashians.

One night, I woke up to use the restroom and I physically couldnt decide up my telephone. I assumed it was unusual however possibly I simply slept on my arms bizarre and I used to be so drained, I didnt must be checking my telephone at that hour anyway. I fell proper again asleep, she wrote.

I woke up that morning and I still couldnt decide up my telephone. I used to be freaking outI couldnt even decide up a toothbrush, my arms damage so badly.

She went on to disclose the ache as soon as turned so unhealthy she wasnt in a position to do up her bra earlier than an occasion.

Fearing the worst, she knew one thing was improper and it wasnt simply on the skin-level anymore.

I remember I had a press day for my Carolina Lemke sunglasses and I was wearing these purple boots and snake-print pants and I couldnt get my pants all the way down to go to the toilet, she wrote.

I couldnt even get my bra on that day, and I needed to have somebody gown me as a result of the ache was so insufferable. With the boots I used to be sporting, my ankles began to really feel it in these joints. Thats once I knew it wasnt simply a problem in my arms, it was a bone drawback.

Now, Kim admits shes come to phrases with the situation, wanting to indicate it off solely eager to cowl it up when she doesnt need it to be a distraction.

Her admission comes days after the most recent episode of her E! actuality present, the place we see Kim obtain her check outcomes.

The physician recognized her with a kind arthritis brought on by psoriasis, and never lupus. Consequently, her joints are affected, inflicting them to grow to be swollen, stiff and painful.

Should youve received a narrative, video or photos get in contact with the Metro.co.uk Leisure group by emailing us heraldpublicist@gmail.com, calling 020 3615 2145 or by visiting our Submit Stuff web page we might love to listen to from you.

MORE: Lil Simz says Drake needed to maintain Prime Boy season three true to itself and the forged at the moment are like family

MORE: Liam Gallagher will get emotional as he addresses Keith Flints dying: Its horrible he received to that stage

Kim Kardashian suffering from psoriatic arthritis? – Times Now

Posted on September 22, 2019 by Dook Domini

Kim Kardashian suffering from psoriatic arthritis?

American beauty mogul Kim Kardashian recently opened up about her battle with Psoriasis, a chronic skin condition caused by an overactive immune system and its repercussions. The 38-year-old Keeping Up With the Kardashiansstar has talked about dealing with psoriasis disease for years which causes red, scaly and often itching or burning patches on the skin.

On the recent episode of the show, Kim learned that she is likely to be suffering from psoriatic arthritis, an inflammatory form of arthritis that causes joint pain and stiffness and affects about 30 per cent of people with psoriasis, according to the National Psoriasis Foundation, reported E-News.

In an essay written on sister Kourtney Kardashian's website 'Poosh' on Thursday, the model wrote that she had her first psoriasis suddenly showed up when she was 25 and said that she has had many more over the years.

"For the past eight years, although the spots are unpredictable, I can always count on my main spot on my right lower leg, which consistently stays flared up," she continued.

"I have learned to live with this spot without using any creams or medication--I just deal. Sometimes I cover it up and sometimes I don't. It doesn't really bother me."

The beauty star also confessed that the disease "got extremely bad" earlier this year, with lesions covering her face and the majority of her body, which led to different symptoms.

"One night, I woke up to use the restroom and I physically couldn't pick up my phone. I thought it was strange but maybe I just slept on my hands weird and I was so tired, I didn't need to be checking my phone at that hour anyway. I fell right back asleep. I woke up that morning and I still couldn't pick up my phone. I was freaking out--I couldn't even pick up a toothbrush, my hands hurt so badly," she wrote.

"As the day went on, I got a bit more movement in my hands, but they really hurt from the inside--I felt it in my bones."

Kim also reports to a rheumatologist that she is suffering from swollen joints, headaches and general fatigue. She tests positive for antibodies linked to lupus and rheumatoid arthritis. After undergoing an ultrasound exam, it is revealed that she has neither disease, but her doctor does tell her that she "probably" has psoriatic arthritis. (ANI)

Continue reading here:

Kim Kardashian suffering from psoriatic arthritis? - Times Now

Psoriasis: Pictures, Symptoms, Causes, Diagnosis, Treatment

Posted on May 5, 2019 by Dook Domini

Articles OnPsoriasis Psoriasis Psoriasis - Psoriasis What Is Psoriasis?

Psoriasis is a skin disorder that causes skin cells to multiply up to 10 times faster than normal. This makes the skin build up into bumpy red patches covered with white scales. They can grow anywhere, but most appear on the scalp, elbows, knees, and lower back. Psoriasis can't be passed from person to person. It does sometimes happen in members of the same family.

Psoriasis usually appears in early adulthood. For most people, it affects just a few areas. In severe cases, psoriasis can cover large parts of the body. The patches can heal and then come back throughout a person's life.

The symptoms of psoriasis vary depending on the type you have. Some common symptoms for plaque psoriasis -- the most common variety of the condition -- include:

People with psoriasis can also get a type of arthritis called psoriatic arthritis. It causes pain and swelling in the joints. The National Psoriasis Foundation estimates that between 10% to 30% of people with psoriasis also have psoriatic arthritis.

Other types of psoriasis include:

No one knows the exact cause of psoriasis, but experts believe that its a combination of things. Something wrong with the immune system causes inflammation, triggering new skin cells to form too quickly. Normally, skin cells are replaced every 10 to 30 days. With psoriasis, new cells grow every 3 to 4 days. The buildup of old cells being replaced by new ones creates those silver scales.

Psoriasis tends to run in families, but it may be skip generations. For instance, a grandfather and his grandson may be affected, but not the child's mother.

Things that can trigger an outbreak of psoriasis include:

Physical exam. Its usually easy for your doctor to diagnose psoriasis, especially if you have plaques on areas such as your:

Your doctor will give you a full physical exam and ask if people in your family have psoriasis.

Lab tests. The doctor might do a biopsy -- remove a small piece of skin and test it to make sure you dont have a skin infection. Theres no other test to confirm or rule out psoriasis.

Luckily, there are many treatments. Some slow the growth of new skin cells, and others relieve itching and dry skin. Your doctor will select a treatment plan that is right for you based on the size of your rash, where it is on your body, your age, your overall health, and other things. Common treatments include:

Treatments for moderate to severe psoriasis include:

Theres no cure, but treatment greatly reduces symptoms, even in serious cases. Recent studies have suggested that when you better control the inflammation of psoriasis, your risk of heart disease, stroke, metabolic syndrome, and other diseases associated with inflammation go down.

Psoriasis affects:

SOURCES:

National Institute of Arthritis and Musculoskeletal and Skin Disease.

National Psoriasis Foundation.

The Psoriasis Foundation.

American Academy of Dermatology.

UpToDate: Epidemiology, clinical manifestations, and diagnosis of psoriasis.

FDA: "FDA approves new psoriasis drug Taltz," FDA approves Amjevita, a biosimilar to Humira.

Medscape: "FDA OKs Biologic Guselkumab (Tremfya) for Plaque Psoriasis."

National Psoriasis Foundation: Statistics.

PubMed Health: "Plaque Psoriasis."

World Health Organization: Global report on psoriasis.

Pagination

Continued here:

Psoriasis: Pictures, Symptoms, Causes, Diagnosis, Treatment

Psoriasis Treatment, Causes, Pictures, Symptoms, Types & Diet

Posted on May 5, 2019 by Dook Domini

REFERENCES:

Alwan, W., and F.O. Nestle. "Pathogenesis and Treatment of Psoriasis: Exploiting Pathophysiological Pathways for Precision Medicine." Clin Exp Rheumatol 33 (Suppl. 93): S2-S6.

Arndt, Kenneth A., eds., et al. "Topical Therapies for Psoriasis." Seminars in Cutaneous Medicine and Surgery 35.2S Mar. 2016: S35-S46.

Benhadou, Fairda, Dillon Mintoff, and Vronique del Marmol. "Psoriasis: Keratinocytes or Immune Cells -- Which Is the Trigger?" Dermatology Dec. 19, 2018.

Conrad, Curdin, Michel Gilliet. "Psoriasis: From Pathogenesis to Targeted Therapies." Clinical Reviews in Allergy & Immunology Jan. 18, 2015.

Dowlatshahi, E.A., E.A.M van der Voort, L.R. Arends, and T. Nijsten. "Markers of Systemic Inflammation in Psoriasis: A Systematic Review and Meta-Analysis." British Journal of Dermatology 169.2 Aug. 2013: 266-282.

Georgescu, Simona-Roxana, et al. "Advances in Understanding the Immunological Pathways in Psoriasis." International Journal of Molecular Sciences 20.739 Feb. 10, 2019: 2-17.

Greb, Jacqueline E., et al. "Psoriasis." Nature Reviews Disease Primers 2 (2016): 1-17.

Kaushik, Shivani B., and Mark G. Lebwohl. "Review of Safety and Efficacy of Approved Systemic Psoriasis Therapies." International Journal of Dermatology 2018.

National Psoriasis Foundation. "Systemic Treatments: Biologics and Oral Treatments." 1-25.

Ogawa, Eisaku, Yuki Sato, Akane Minagawa, and Ryuhei Okuyama. "Pathogenesis of Psoriasis and Development of Treatment." The Journal of Dermatology 2017: 1-9.

Stiff, Katherine M., Katelyn R. Glines, Caroline L. Porter, Abigail Cline & StevenR. Feldman. "Current pharmacological treatment guidelines for psoriasis and psoriaticarthritis." Expert Review of Clinical Pharmacology (2018).

Villaseor-Park, Jennifer, David Wheeler, and Lisa Grandinetti. "Psoriasis: Evolving Treatment for a Complex Disease." Cleveland Clinic Journal of Medicine 79.6 June 2012: 413-423.

Woo, Yu Ri, Dae Ho Cho, and Hyun Jeong Park. "Molecular Mechanisms and Management of a Cutaneous Inflammatory Disorder: Psoriasis." International Journal of Molecular Sciences 18 Dec. 11, 2017: 1-26.

Follow this link:

Psoriasis Treatment, Causes, Pictures, Symptoms, Types & Diet

Psoriasis – MedicineNet

Posted on April 27, 2019 by Dook Domini